Amadix — Series B (estimated) · €532K

Capital increase of €532,000 in which CDTI, through its Innvierte co-investment programme, invested €252,000 alongside the CRB Bio II fund managed by CRB Inverbío. The money was to finish the European clinical validation of the Colofast colorectal cancer test and bring it to market during 2021.

LeadCRB Inverbío RoundSeries B (estimated) Announced27 Oct 2020 CityValladolid SectorHealthtech & Bio · Healthtech Source W

Something wrong? Suggest a correction →